Afya (AFYA) Q4 2022: Digital B2B Revenue Soars 154%, Fueling Ecosystem Expansion
Afya’s digital B2B revenue surged 154% in 2022, underscoring the company’s pivot to a multi-pronged healthcare education and services platform. Margin stability is challenged by segment mix shifts and MedCell headwinds, but core medical education continues to anchor predictable growth. Robust cash flows and disciplined capital allocation position Afya to capitalize on regulatory tailwinds and continued expansion of its digital and continuing education ecosystem.
Summary
- Digital B2B Acceleration: B2B contracts with pharma drove triple-digit digital revenue growth, broadening Afya’s ecosystem reach.
- Margin Mix Pressure: Expansion in lower-margin digital and continuing education segments tempers overall margin gains.
- Regulatory Tailwinds Loom: Anticipated Mais Médicos expansion could unlock new medical seat growth and pricing power stability.
Business Overview
Afya is Brazil’s leading integrated medical education and digital health platform, generating revenue from three core segments: undergraduate medical education (tuition from medical students), continuing education (postgraduate and specialty courses), and digital health services (B2P, business-to-physician, and B2B, business-to-business, contracts with pharma and healthcare organizations). The company’s business model blends high-visibility, regulated medical school revenue with scalable digital and B2B solutions, targeting both students and practicing physicians.
Performance Analysis
Afya delivered robust top-line growth, with adjusted net revenue up 32% year-over-year, driven by higher medical tuition, new campus openings, and a sharp rebound in continuing education. The digital services segment posted a 25% revenue increase, propelled by a 154% surge in B2B revenue from nearly 100 contracts with 45 pharmaceutical companies. However, margin expansion was muted by a mix shift toward lower-margin segments and underperformance in MedCell, the residency prep business.
Undergraduate medical education remains the cornerstone, now comprising 18,000 students and 3,163 approved medical seats, representing 77% of tuition revenue. Cash conversion stayed strong at 94%, supporting continued investments and share repurchases. Despite MedCell’s revenue drop amid intense competition, management executed price hikes and product overhauls to stabilize the prep business for future cycles.
- Digital B2B Outperformance: B2B digital revenue grew 154%, highlighting Afya’s penetration into pharma and healthcare verticals.
- Continuing Education Recovery: Revenues jumped 49% as in-person classes and new campuses ramped post-pandemic.
- Stable Core Margins: Medical undergrad margins remained steady, cushioning volatility in newer segments.
The company’s capital allocation discipline, including three buyback programs and targeted acquisitions, further supported EPS growth and reinforced Afya’s reputation as a consolidator in Brazil’s medical education market.
Executive Commentary
"We are delighted to see that the most significant growth of the year in terms of revenue comes from our continued education sector...our ecosystem has 260,000 active users, representing a great penetration among physicians and medical students in Brazil."
Virgílio Gibon, CEO
"All this effort means one thing, our medical education business remains and will continue to be the cornerstone of our business...delivering high predictable growth, combined with solid profitability and cash generation."
Luiz André Blanco, CFO
Strategic Positioning
1. Digital Ecosystem Expansion
Afya’s aggressive digital B2B push—anchored by contracts with pharma and healthcare organizations—has unlocked new revenue streams and expanded its addressable market. The company’s digital ecosystem now reaches 260,000 monthly active users, nearly 40% of all physicians and medical students in Brazil.
2. Medical Education Scale and Resilience
With over 3,100 approved medical seats and 100% occupancy, Afya’s undergraduate segment provides stable, predictable cash flows. Tuition increases and new campus integration bolster this core, even as the company invests in adjacent segments.
3. Continuing Education Growth Opportunity
Post-pandemic normalization and the launch of seven new units have reignited continuing education growth, with management targeting 10,000 students by 2026. This segment benefits from a growing market of physicians seeking ongoing training, and Afya is outpacing market growth.
4. Margin Management Amid Segment Mix Shift
Margin headwinds stem from rapid growth in digital and continuing education, both of which carry structurally lower margins than the core undergrad business. Management is focused on cost discipline and operational leverage as new units ramp and fixed costs are absorbed.
5. Regulatory and Policy Leverage
Potential expansion of the Mais Médicos program could further increase medical seat supply, particularly in underserved regions, positioning Afya to capture incremental demand and maintain pricing power.
Key Considerations
This quarter highlighted Afya’s ability to blend legacy education stability with digital-led growth, while navigating competitive and regulatory complexity. Investors should weigh the following:
- Digital B2B as a Growth Engine: Pharma and healthcare partnerships are scaling faster than expected, but require continued investment and execution to sustain momentum.
- MedCell Turnaround Efforts: Despite a challenging prep course environment, management has enacted pricing and product changes, with impact expected in the next cycle.
- Segment Mix and Margin Evolution: Lower-margin digital and continuing education growth dilutes group margin, but higher fixed-cost absorption and maturation could offset this over time.
- Regulatory Catalysts: Upcoming government programs may unlock new capacity and support tuition pricing, but timing and scale remain uncertain.
Risks
Competitive pressure in residency prep (MedCell) and continued education could suppress growth and profitability if turnaround efforts lag. Regulatory uncertainty around medical seat authorizations and Mais Médicos expansion may affect enrollment and pricing. Segment mix shifts toward lower-margin digital and continuing education businesses could further dilute margins if operational leverage does not materialize. Seasonality and cash flow timing differences also add volatility to quarterly results.
Forward Outlook
For Q1 2023, Afya guided to:
- Adjusted net revenue between R$2.75 billion and R$2.85 billion
- Adjusted EBITDA between R$1.1 billion and R$1.2 billion (excluding post-guidance acquisitions)
For full-year 2023, management expects:
- 100% occupancy in all medical schools and continued digital and continuing education growth
Management highlighted:
- Continued maturation of new campuses and digital B2B revenue streams
- Potential regulatory announcements that could expand medical seat supply
Takeaways
Afya’s quarter demonstrates a disciplined balance between high-visibility core education and high-growth digital expansion, with management proactively addressing competitive and regulatory risks.
- Digital Revenue Inflection: B2B digital acceleration is reshaping the company’s growth profile, but requires ongoing investment and execution discipline.
- Margin Evolution Watchpoint: Segment mix and MedCell headwinds will be key in determining whether Afya can sustain profitability as new businesses scale.
- Regulatory Leverage: Investors should monitor Mais Médicos policy developments and seat authorizations as potential upside catalysts for core education growth.
Conclusion
Afya’s Q4 results reinforce its status as Brazil’s medical education leader, now augmented by a rapidly scaling digital health ecosystem. While competitive and margin pressures persist, the company’s diversified model and strong cash generation position it well for both organic and policy-driven expansion in the coming years.
Industry Read-Through
Afya’s triple-digit digital B2B growth signals a broader shift in healthcare education toward integrated, platform-based models that combine traditional learning with digital solutions for professionals and industry stakeholders. Competitors in education and digital health should note the importance of ecosystem reach and pharma partnerships as new sources of recurring revenue. Regulatory policy remains a major variable for the sector, with seat expansions and regional incentives likely to shape capacity, pricing, and long-term growth for all medical education providers in Brazil.